


Contents lists available at ScienceDirect

Neurobiology of Disease



journal homepage: www.elsevier.com/locate/ynbdi

Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study

Enrico Premi^{a,1}, Marta Pengo^{b,c,1}, Irene Mattioli^c, Valentina Cantoni^c, Juergen Dukart^{d,e}, Roberto Gasparotti^f, Emanuele Buratti^g, Alessandro Padovani^{a,c}, Martina Bocchetta^{h,i}, Emily G. Todd^h, Arabella Bouzigues^h, David M. Cash^{h,j}, Rhian S. Convery^h, Lucy L. Russell^h, Phoebe Foster^h, David L. Thomas^k, John C. van Swieten¹, Lize C. Jiskoot¹, Harro Seelaar¹, Daniela Galimberti^{m,n}, Raquel Sanchez-Valle^o, Robert Laforce Jr^p, Fermin Moreno^q, Matthis Synofzik^{r,s}, Caroline Graff^{t,u}, Mario Masellis^v, Maria Carmela Tartaglia^w, James B. Rowe^x, Kamen A. Tsvetanov^x, Rik Vandenberghe^y, Elizabeth Finger^z, Pietro Tiraboschi^{aa}, Alexandre de Mendonça^{ab}, Isabel Santana^{ac}, Chris R. Butler^{ad}, Simon Ducharme^{ae}, Alexander Gerhard^{af,ag}, Johannes Levin^{ah,ai,aj}, Markus Otto^{ak}, Sandro Sorbi^{al,am}, Isabelle Le Ber^{an,ao,ap,aq}, Florence Pasquier^{ar,as,at}, Jonathan D. Rohrer^h, Barbara Borroni^{a,c,*}, on behalf of the Genetic Frontotemporal dementia Initiative (GENFI)

^a Neurology, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy

^c Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

^d Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), Research CentreJülich, Jülich, Germany

- ^e Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- ^f Neuroradiology Unit, Department of Medical and Surgical Specialties, University of Brescia, Brescia, Italy
- g ICGEB, Trieste, Italy
- h Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom

¹ Centre for Cognitive and Clinical Neuroscience, Division of Psychology, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, United Kingdom

- ^j Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
- ^k Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom
- ¹ Department of Neurology and Alzheimer center, Erasmus Medical Center Rotterdam, the Netherlands
- ^m Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
- ⁿ Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
- ^o Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain
- ^p Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, Faculté de Médecine, Université Laval, Québec, Canada
- ^q Hospital Universitario Donostia, San Sebastian, Spain

^r Division Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany

- ^s German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- ^t Karolinska Institutet, Department NVS, Division of Neurogeriatrics, Stockholm, Sweden
- ^u Unit for Hereditray Dementia, Theme Aging, Karolinska University Hospital, Solna, Stockholm, Sweden
- ^v Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, ON, Canada
- W Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, ON, Canada
- ^x Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom
- ^y Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
- ^z Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
- ^{aa} Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Carlo Besta, Milan, Italy
- ^{ab} Faculty of Medicine, University of Lisbon, Lisbon, Portugal
- ^{ac} Neurology Department, Centro Hospitalar e Universitário de Coimbra, Portugal
- ^{ad} Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom
- ^{ae} Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada

https://doi.org/10.1016/j.nbd.2023.106068

Received 5 February 2023; Received in revised form 1 March 2023; Accepted 4 March 2023 Available online 8 March 2023 0969-0961 (Crown Copyright © 2023 Published by Elsevier Inc. This is an open access article under the

0969-9961/Crown Copyright © 2023 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

^b Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

^{*} Corresponding author at: Clinica Neurologica, Dipartimento Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy.

E-mail address: bborroni7@gmail.com (B. Borroni).

^{af} Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom

ag Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Germany

^{ah} Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, Germany

^{ai} German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

^{aj} Munich Cluster of System Neurology, Munich, Germany

ak Department of Neurology, University Hospital Halle, Halle, Germany

^{al} Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy

am IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

an Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France

ao Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France

^{ap} Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France

^{aq} Reference Network for Rare Neurological Diseases (ERN-RND)

^{ar} University of Lille, France

as Inserm 1172, Lille, France

at CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France

ARTICLE INFO

Frontotemporal dementia

Magnetic resonance imaging

Neurotransmitters

Positron emission tomography

Frontotemporal lobar degeneration

Keywords:

Genes

Mutation

ABSTRACT

Background: Neurotransmitters deficits in Frontotemporal Dementia (FTD) are still poorly understood. Better knowledge of neurotransmitters impairment, especially in prodromal disease stages, might tailor symptomatic treatment approaches.

Methods: In the present study, we applied JuSpace toolbox, which allowed for cross-modal correlation of Magnetic Resonance Imaging (MRI)-based measures with nuclear imaging derived estimates covering various neurotransmitter systems including dopaminergic, serotonergic, noradrenergic, GABAergic and glutamatergic neurotransmission.

We included 392 mutation carriers (157 *GRN*, 164 *C9orf72*, 71 *MAPT*), together with 276 non-carrier cognitively healthy controls (HC). We tested if the spatial patterns of grey matter volume (GMV) alterations in mutation carriers (relative to HC) are correlated with specific neurotransmitter systems in prodromal (CDR® plus NACC FTLD = 0.5) and in symptomatic (CDR® plus NACC FTLD \geq 1) FTD.

Results: In prodromal stages of *C9orf72* disease, voxel-based brain changes were significantly associated with spatial distribution of dopamine and acetylcholine pathways; in prodromal *MAPT* disease with dopamine and serotonin pathways, while in prodromal *GRN* disease no significant findings were reported (p < 0.05, Family Wise Error corrected). In symptomatic FTD, a widespread involvement of dopamine, serotonin, glutamate and acetylcholine pathways across all genetic subtypes was found. Social cognition scores, loss of empathy and poor response to emotional cues were found to correlate with the strength of GMV colocalization of dopamine and serotonin pathways (all p < 0.01).

Conclusions: This study, indirectly assessing neurotransmitter deficits in monogenic FTD, provides novel insight into disease mechanisms and might suggest potential therapeutic targets to counteract disease-related symptoms.

1. Introduction

Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by progressive behavioral, linguistic, dysexecutive and motor disturbances (Rascovsky et al., 2011; Gorno-Tempini et al., 2011). Its causes are genetic in about a third of cases, with mutations in microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72) being the commonest causes (Borroni and Padovani, 2013; Greaves and Rohrer, 2019). Behavioral variant FTD (bvFTD) is the most common presentation, followed by Primary Progressive Aphasias (PPAs) (Greaves and Rohrer, 2019). Symptomatic MAPT mutation carriers show a symmetrical brain atrophy involving mainly the anteromedial temporal lobes, symptomatic GRN mutation carriers exhibit a striking asymmetrical pattern of cortical atrophy, whereas symptomatic C9orf72 mutation carriers display diffuse and symmetric cortical atrophy, involving also posterior regions, thalamus and cerebellum (Cash et al., 2018; Boeve et al., 2012; Whitwell et al., 2012). Early neuroimaging alterations are described around 5–10 years before phenoconversion with a specific distribution in each group (Rohrer et al., 2015).

Despite the continuous advancement of knowledge on diseaserelated mechanisms, little is known about neurotransmitter processes that occur in FTD. Exploring neurotransmitter pathways involved might shed more light on disease pathogenesis; moreover, since each mutation group is characterized by different clinical and imaging features, we might hypothesise that different neurotransmitter pathways are involved. As a consequence, research in this field might aid in identify tailored therapeutic targets for symptomatic interventions. Although impairment of dopaminergic, serotoninergic, GABAergic and glutamatergic pathways in autopsy studies has been demonstrated (Murley and Rowe, 2018), clinical trials have failed to report substantial benefits from neurotransmitter modulation on clinical symptoms in FTD (Panza et al., 2020). This discrepancy may be due to weaknesses in research methodology and small studies in unstratified populations.

Recent advancements in positron emission tomography (PET) and single photon computed emission tomography (SPECT) tracer development resulted in novel tracers that can reliably measure the availability of specific receptors. However, the need of large samples and of comparing multiple tracers in the same subjects have prevented reliable results on in vivo neurotransmitter pathways in neurodegenerative disorders, and especially in FTD. Indeed, only a few small series studies or case reports are available in FTD and in FTD-related mutations (Sperfeld et al., 1999; Miyoshi et al., 2010; Meloni et al., 2017; Carecchio et al., 2014; Leuzy et al., 2016; Takeshige et al., 2018; Murley et al., 2020).

To fill this gap, JuSpace toolbox has been recently developed with the aim to gather neurotransmitter pathways abnormalities combining MRI-based measures and a list of included PET and SPECT maps covering various neurotransmitter pathways (Dukart et al., 2018). JuSpace considers spatial pattern of brain alterations based on MRI measures derived by comparison between different groups (e.g. patients versus healthy controls), and it performs a correlation between these alterations and each receptor/transporter map included in the toolbox (Dukart et al., 2021). JuSpace therefore is able to explore if the spatial patterns of observed brain changes in the disease of interest are related to the distribution of specific neurotransmitters pathways, as derived from independent healthy volunteer populations.

In the present study, we aimed to indirectly unravel neurotransmitter pathways changes, in particular in the earliest disease phases, namely in prodromal FTD, and to assess correlation with clinical symptoms. To achieve this, we applied JuSpace tool on a large sample of subjects from the international Genetic FTD Initiative (GENFI), considering individuals at different disease stages and with different pathogenetic mutations, and we evaluated impairment of dopamine, serotonin, glutamate, GABA, noradrenaline and acetylcholine systems.

2. Methods

2.1. Subjects

Data for this study were drawn from the GENFI multicenter cohort study, which consists of 26 research centers in Europe and Canada. Inclusion and exclusion criteria have been previously described (Rohrer et al., 2015). Local ethics committees approved the study at each site and all participants provided written informed consent according to the Declaration of Helsinki.

We considered both symptomatic patients fulfilling current clinical criteria for FTD (Rascovsky et al., 2011; Gorno-Tempini et al., 2011), and asymptomatic participants *at risk* to carry *GRN*, *C9orf72* or *MAPT* mutations. Between January 2012 and March 2020, we considered 668 participants, of which 392 were mutation carriers (157 with *C9orf72*, 164 with *GRN*, and 71 with *MAPT* mutations) and 276 were mutation non-carriers. Mutation carriers were grouped according to disease severity, as measured by Clinical Dementia Rating Dementia Staging Instrument plus behaviour and language domains from the National Alzheimer's Coordinating Center and Frontotemporal lobar degeneration modules (CDR® plus NACC FTLD, from here on referred as CDR) (Miyagawa et al., 2020) into asymptomatic subjects (CDR = 0), prodromal FTD (CDR = 0.5) or symptomatic FTD patients (CDR \geq 1). Mutation non-carriers were considered as healthy control group (HC).

Included subjects underwent a careful recording of demographic data and a standardized clinical and neuropsychological assessment, as previously published (Premi et al., 2019).

2.2. MRI acquisition

MRI protocol was common to all the GENFI sites, and adapted for different scanners. Each subject underwent a 3 T MRI at each local site from three different manufacturers (Philips Healthcare-215 subjects, GE Healthcare Life Sciences- 19 subjects, Siemens Healthcare Diagnostic-434 subjects). The protocol included a volumetric T1-weighted MRI scan (magnetization-prepared rapid gradient echo, MPRAGE), as previously reported (Rohrer et al., 2015; Premi et al., 2017; Cash et al., 2018; Gazzina et al., 2019; Borrego-Écija et al., 2021). During scanning, subjects were asked to keep their eyes closed, not to think of anything in particular, and not to fall asleep.

2.3. MRI preprocessing and analyses

T1-weighted images were processed and analysed with the voxelbased morphometry (VBM) pipeline implemented in the Computational Anatomy Toolbox (CAT12 v.1742) (www.neuro.uni-jena.de/cat) for SPM12 (SPM12 v.7219) (www.fil.ion.ucl.ac.uk/spm/softw are/spm12) running on MATLAB R2019b (the MathWorks, Inc., Natick, Massachusetts, United States). The VBM pipeline consists of several stages (tissue segmentation, spatial normalization to a standard Montreal National Institute [MNI] template, modulation and smoothing), as previously described (Kurth et al., 2015). CAT12 potentially provides more robust and accurate performances compared to other VBM pipelines (Farokhian et al., 2017). The normalized and modulated grey matter images were then smoothed with 8 mm full width at halfmaximum Gaussian kernel to reduce the probability of misalignment errors, increasing the chance to detect differences over small regions of the brain.

To test for group differences in grey matter volume (GMV) a General Linear Model using SPM12 was implemented, considering age, gender and site as nuisance variables. The statistical threshold was set to p < 0.05 corrected for multiple comparisons (whole-brain family-wise error, FWE).

2.4. Spatial correlation with neurotransmitter density maps

We used the JuSpace toolbox to test if the spatial patterns of GMV alterations in asymptomatic, prodromal and symptomatic FTD subjects (relative to HC) are correlated with specific neurotransmitter systems (Dukart et al., 2021). We considered a list of included PET and SPECT maps in JuSpace toolbox, covering various neurotransmitter systems (Dukart et al., 2021).

JuSpace creates a spatial pattern of GMV, comparing two different groups (e.g. patients versus healthy controls), and therefore aims to assess if the spatial patterns of brain changes observed in patients (as compared to healthy controls) are related to the distribution of specific neurotransmitters systems, these latter derived from independent healthy volunteer populations (Dukart et al., 2021). Thus, it performs a correlation between these alterations and each receptor/transporter map included in the toolbox.

Confounding effects of age, gender and site were regressed out from all images prior to these analyses (Dukart et al., 2021).

We considered serotonin transmission, i.e. the 5-hydroxytryptamine 1a (5-HT1a) receptor, the 5-HT1b receptor, the 5-HT2a receptor, and the serotonin transporter SERT; dopamine transmission, i.e. the D1 receptor, the D2 receptor, the dopamine transporter (DAT), and the FluoroDOPA, the GABAa receptors, the vesicular acetylcholine transporter (VAChT), the metabotropic glutamate receptor type 5 (mGLUR5), and the noradrenaline transporter (NAT). Each map included in Juspace toolbox was derived by PET data with the exception of DAT, which was derived from SPECT data, and each map was built up with specific numbers of healthy volunteers (Supplementary Table 1 for details). Using JuSpace toolbox, native normalized, modulated and smoothed grey matter images were parceled in regions of interest using the Neuromorphometrics Atlas (MICCAI 2012 Grand Challenge and Workshop on Multi-Atlas Labeling. www.masi.vuse.vanderbilt.edu/workshop2012/index.ph p/Challenge Details). Mean regional values of GMV were extracted for all patients and HC. Spearman correlation coefficients (Fisher's Z transformed) were calculated between these z-transformed GMV maps of the patients and the spatial distribution of the respective neurotransmitter maps included in JuSpace toolbox. Exact permutation-based p-values as included in JuSpace (10,000 permutations randomly assigning group labels using orthogonal permutations) were computed to check if the distribution of the observed Fisher's z-transformed individual correlation coefficients were significantly different from zero. All analyses were Family Wise Error (FWE) corrected for the number of tests. Spearman correlation coefficients (Fisher's Z transformed) were calculated between these z-transformed GMV maps and the spatial distribution of the respective neurotransmitter maps. Exact permutationbased p-values as implemented in JuSpace (10,000 permutations randomly assigning group labels using orthogonal permutations) were computed to test if the observed correlation coefficients across patients deviate from a null distribution.

2.5. Statistical analysis

Comparisons of demographic and clinical characteristics were performed by the Student's *t*-test for continuous variables and the χ^2 test for categorical variables.

Spearman correlation was used to assess the relationship between each neurotransmitter output obtained with Juspace (i.e., the GMVneurotransmitters correlation, Fisher's Z transformed) and clinical or behavioral data. Statistical significance was set at p < 0.05, corrected for multiple comparisons (Family Wise Error-FWE) (SPSS Statistics 22.0, Chicago, USA).

3. Results

3.1. Participants

Demographic characteristics of mutation carriers and non-carriers are reported in Table 1. In the present study, we considered 157 C9orf72 expansion carriers, namely 85 asymptomatic, 33 prodromal and 39 symptomatic subjects; 164 with GRN mutation carriers, namely 107 asymptomatic, 33 prodromal and 24 symptomatic subjects, and 71 MAPT mutation carriers, namely 39 asymptomatic, 18 prodromal and 14 symptomatic subjects.

Standard voxel-wise analyses of GMV demonstrated the typical pattern of brain atrophy in mutations subgroups, according to disease stage, as previously published (Rohrer et al., 2015; Cash et al., 2018; Beck et al., 2008; Boeve et al., 2012; Josephs et al., 2009; Mahoney et al., 2012; Sha et al., 2012; Whitwell et al., 2012) (see Supplementary Fig. 1).

3.2. Neurotransmitters deficits in C9orf72 expansion carriers

In prodromal stage of C9orf72 disease (CDR = 0.5), as compared to HC, voxel-based brain changes were significantly associated with spatial distribution of dopamine transporter DAT (r = -0.13, p = 0.02) and acetylcholine transporter (r = -0.12, p = 0.02). In fully symptomatic stage (CDR > 1), additional voxel-based brain changes were significantly associated with spatial distribution of.

5-HT1a receptors (r = -0.30, p = 0.01), D1 receptors (r = -0.28, p =0.01), FDOPA (r = -0.13, p = 0.02), and mGluR5 (r = -0.20, p = 0.01) (see Fig. 1 and Table 2). The negative correlation coefficients indicate GMV reduction in patients as compared to HC in areas with high neurotransmitters density.

There was no significant difference in spatial distribution in asymptomatic expansion carriers (CDR = 0) as compared to HC.

3.3. Neurotransmitters deficits in GRN mutation carriers

No voxel-based brain changes were significantly associated with neurotransmitter spatial distribution in prodromal GRN disease (CDR = 0.5). In fully symptomatic stage (CDR > 1), as compared to HC, voxelbased brain changes were significantly associated with spatial distribution of 5-HT1a receptors (r = -0.25, p = 0.01), D1 receptors (r =-024, p = 0.01), dopamine transporter DAT (r = -0.14, p = 0.01), FDOPA (r = -0.11, p = 0.02), acetylcholine transporter (r = -0.16, p =0.02), and mGluR5 (r = -0.23, p = 0.01) (see Fig. 1 and Table 2).

There was no significant difference in spatial distribution in asymptomatic mutation carriers (CDR = 0) as compared to HC.

Table 1

Table 1	
Demographic and clinical	characteristics of the studied group.

Variable	HC	C9orf72	GRN	MAPT	p- value*
Number	276	157	164	71	
	46.5 \pm	49.6 \pm	48.5 \pm	44.6 \pm	
Age, years	13.2	13.2	12.9	12.8	0.02
Sex, female %	57.6	54.1	59.8	52.1	0.14^
Education,	14.3 \pm		$14.2 \pm$	14.6 \pm	
years	3.3	14.0 ± 3.2	3.8	3.0	0.56

Demographic characteristics are expressed as mean \pm standard deviation, unless otherwise specified. HC = Healthy controls, C9orf72 = chromosome 9 open reading frame 72 mutation carriers; GRN = progranulin mutation carriers; MAPT = microtubule-associated protein tau mutation carriers; *Student-t-test, unless otherwise specified; ^ Chi-Square test.

3.4. Neurotransmitters deficits in MAPT mutation carriers

In prodromal stage of *MAPT* disease (CDR = 0.5), as compared to HC, voxel-based brain changes were significantly associated with spatial distribution of 5-HT1a receptors (r = -0.34, p = 0.01), D1 receptors (r =-0.20, p = 0.01), dopamine transporter DAT (r = -0.30, p = 0.01), FDOPA (r = -0.16, p = 0.01), and SERT (r = -0.16, p = 0.01). In fully symptomatic stage (CDR \geq 1), additional voxel-based brain changes were significantly associated with spatial distribution of 5-HT1b receptors (r = 0.14, p = 0.02) and acetylcholine transporter (r = -0.18, p= 0.02) (see Fig. 1 and Table 2).

There was no significant difference in spatial distribution in asymptomatic mutation carriers (CDR = 0) as compared to HC.

3.5. Neurotransmitter impairment and social cognition in monogenic FTD

We assessed the relationship between GMV-neurotransmitters correlation coefficients and social cognition/loss of empathy data in monogenic FTD patients (CDR > 0). We considered only GMVneurotransmitters correlation coefficients significantly impaired in FTD and we excluded those highly correlated to each other (Spearman correlations coefficients>0.80), namely FDOPA. Thus, we included in the present analyses 5-HT1a receptors, D1 receptors, DAT, VAchT, and mGLUR5.

We considered a) Ekman facial emotion recognition task and Fauxpas recognition test (mini-SEA) scores (the lower the scores the worse the performances) (Funkiewiez et al., 2012), and b) loss of empathy and c) poor response to social/emotional cues, as reported by caregiver (which were rated on a 5-point scale: 0 = absent, 0.5 = questionable/very mild, 1 = mild, 2 = moderate, and 3 = severe). Significant threshold was set at $p \leq 0.002$, after correction for multiple comparisons.

In C9orf72 expansion carriers, mini-SEA scores (n = 58) were positively correlated with the strength of GMV colocalization of 5HT1a receptors (r = 0.449, p < 0.001) and D1 receptors (r = 0.402, p = 0.002); loss of empathy (n = 71) was negatively correlated with D1 receptors (r = -0.423, p < 0.001) and poor response to emotional cues (n = 71) with 5HT1a receptors (r = -0.406, p < 0.001) and D1 receptors (r = -0.454, p < 0.001). No other significant correlations between cognitive data and GMV neurotransmitters co-localization at pre-established statistical threshold were reported.

In *GRN* mutation carriers, loss of empathy (n = 57) was negatively correlated with D1 receptors (r = -0.439, p = 0.001) and poor response to emotional cues (n = 57) with D1 receptors (r = -0.542, p < 0.001) and DAT (r = -0.497, p < 0.001).

The relatively low number of prodromal or symptomatic MAPT mutation carriers prevented us to run correlation analyses in this group.

4. Discussion

In the last years, a giant step forward has been made in the knowledge of genetic basis of FTD and gene-related pathogenetic mechanisms, and more recently experimental therapeutic trials targeting C9orf72, GRN, or MAPT have been proposed.

Despite this, neurotransmitter impairment in monogenic FTD and differences according to causative gene have not been assessed yet. Restoring these deficits, individually or in combination, has the potential advantage to improve clinical and behavioral symptoms and may help in further understanding of the disease.

In the present work, we investigated if the spatial distribution of grey matter atrophy observed in different subtypes of monogenic prodromal and symptomatic FTD are related to the localization of specific neurotransmitters pathways as derived from independent healthy volunteer populations (Dukart et al., 2021). These data have been obtained by JuSpace toolbox, which compares PET and SPECT derived neurotransmitter maps with other imaging modalities such as MRI data (Dukart

E. Premi et al.

Mutation	C9oi	f72	GR	N	MA	PT
CDR plus NACC FTLD	0.5	<u>></u> 1	0.5	<u>></u> 1	0.5	<u>></u> 1
5HT1a						
5HT1b						
5HT2a						
SERT						
D1						
D2						
DAT						
FDOPA						
GABA -A						
NAT						
VAchT						
mGLUR5						

Fig. 1. Results of spatial correlation analyses according to mutation and disease stage.

Significant correlations for each neurotransmitter map in the different genetic groups are represented, considering each mutation group (*C9orf72, GRN, MAPT*) and disease stage according to Clinical Dementia Rating Dementia Staging Instrument plus behaviour and language domains from the National Alzheimer's Coordinating Center and Frontotemporal lobar degeneration modules (CDR plus NACC FTLD, here referred as CDR).

5HT = 5-hydroxytryptamine; SERT = serotonin transporter; D = dopamine; DAT = dopamine transporter; FDOPA = Fluorodopa; GABAa = γ -Aminobutyric acid type A; NAT = noradrenaline; VAChT = Vesicular acetylcholine transporter; mGLUR5 = metabotropic glutamate receptor type 5.

p-values<0,01 in blue and *p*-values<0.05 in red, corrected for multiple comparisons (Bonferroni's correction). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

et al., 2021). In our study, we considered grey matter atrophy as an imaging marker of neurodegeneration; however, other biomarkers might be even more sensitive, in particular in the prodromal phase (e.g. measures derived from functional imaging data).

We reported that grey matter alterations in the prodromal disease stages specifically co-localised with different neurotransmitters pathways, involving dopamine and cholinergic systems in C9orf72 expansion carriers, dopamine and serotonin in MAPT mutation carriers, and with no significant detectable changes in GRN mutation carriers. Indeed, it has been reported that TDP-43 proteinopathy, the pathological hallmark of C9orf72 expansions, may cause dopamine alterations (Funkiewiez et al., 2012) and that C9orf72 expansion carriers exhibit more pronounced memory deficits as compared to MAPT and GRN mutation carriers (Funkiewiez et al., 2012), tasks for which cholinergic system is key. On the other hand, in regard to MAPT mutations, it has been proposed a link between dopamine and serotonin neurotransmission and phosphorylation state of tau protein (Koppel et al., 2019; Ramos-Rodriguez et al., 2013), with tau being able to disrupt the survival of dopaminergic and serotoninergic neurons in Drosophila and in animal models (Wu et al., 2013; Khan et al., 2022). Finally, the lack of significant findings in GRN mutation carriers is in line with previous imaging studies reporting less functional and structural brain abnormalities in the prodromal stages than other genetic subtypes (Cash et al., 2018; Borroni et al., 2012; Premi et al., 2016; Premi et al., 2021).

Conversely, symptomatic disease was associated with a broad involvement of different circuits and significant changes of dopaminergic, serotoninergic and cholinergic pathways in all monogenic FTD subtypes. We also found additional glutamatergic pathway involvement in *C9orf72* and *GRN* symptomatic mutations carriers. Of note, GABAergic and noradrenergic pathways resulted spared in monogenic FTD. These findings confirm and extend previous literature data on autopsy studies as well as a recent study on a large group of PPA patients (Premi et al., 2022), but also suggest an additional involvement of cholinergic system in monogenic FTD which is absent in sporadic disease (Murley and Rowe, 2018; Benussi et al., 2019). As compared to previous studies (Murley and Rowe, 2018), we indeed failed to confirm a co-localization of grey matter alteration and the GABAergic system.

Interestingly, we also suggest that dopamine and serotonin pathways may be associated with social cognition deficits and loss of empathy, which represents an early clinical feature in FTD (Toller et al., 2023). Dopamine, in addition to be linked to movement disorders, has long been known for its role in reward processing and emotional recognition (Fernandez et al., 2017; Schuster et al., 2022), and most recently a central role of serotonin circuits has been recognized in emotion regulation and social behaviour (Canli and Lesch, 2007; Kanen et al., 2021; Duerler et al., 2022).

Most studies evaluating pharmacological approaches in FTD have not reported clear-cut results (Panza et al., 2020). Findings herein reported argue for further considering pharmacological manipulation of specific neurotransmitters, specifically considering FTD subtypes and disease stage to counteract related symptoms. In this view, investigating neurotransmitter pathways involved might aid in identifying biochemical alterations, which together with clinical, biological and neuroimaging biomarkers might be helpful to characterize more in detail the different FTD subtypes. In comparison to other biomarkers, exploring neurotransmitter impairment might hold the advantage to identify tailored therapeutic targets to improve symptomatic treatment.

Nonetheless, we acknowledge that this study entails some limitations. First, future implemented neurotransmitters maps in JuSpace may further refine the present findings. Moreover, the maps available have been recently obtained, and present some limitations that might to be addressed, e.g. the variability in the number of controls cases in each map and receptor density assessment is not necessarily related to neurotransmitter density. Moreover, JuSpace toolbox has not yet been validated in aging populations with substantial atrophy. Second, we considered prodromal monogenic FTD, and these results cannot be extended to prodromal sporadic disease. Third, other toolbox mapping neurotransmitter systems and their implementation, such as Neuro-Maps, may be also considered (Markello et al., 2022). Finally, JuSpace toolbox indirectly assess neurotransmitter impairment, and post mortem studies are warranted to confirm the results herein observed.

In conclusions, this study suggests that JuSpace is a helpful tool to indirectly assess neurotransmitter deficits in neurodegenerative dementias and may provide novel insight into disease mechanisms and intervention pharmacological targets.

Fundings

This work is supported by JPND grant "GENFI-prox" (2019–02248), the Centre d'Investigation Clinique (ICM, France) and the Centre pour l'Acquisition et le Traitement des Images platform (CATI, France), the UK Medical Research Council, the Italian Ministry of Health (CoEN015 and Ricerca Corrente), and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, a Canadian Institutes of Health Research operating grant, and the Italian Ministry of Health (GR-2018-12365105). This work was also supported by the MRC UK GENFI grant (MR/M023664/1), the Alzheimer's Society grant (AS-PG-16-007), and the Bluefield Project. This work was funded by the

Table 2

Results of spatial correlation analyses for included participants according to mutation subtype and disease stage.

	CDR	= 0.5	$\text{CDR} \geq 1$		
Mutation	r	p-value	r	<i>p</i> -value	
C9orf72					
5HT1a	-0.08	0.38	-0.30	0.01	
5HT1b	0.01	0.98	-0.01	0.91	
5HT2a	-0.01	0.98	-0.09	0.26	
SERT	-0.09	0.08	-0.08	0.91	
D1	-0.01	0.09	-0.28	0.01	
D2	-0.08	0.26	0.02	0.91	
DAT	-0.13	0.02	-0.22	0.01	
FDOPA	-0.05	0.64	-0.13	0.02	
GABAa	0.07	0.98	-0.07	0.91	
NAT	-0.08	0.16	0.04	0.55	
VAchT	-0.12	0.02	-0.20	0.01	
mGluR5	-0.07	0.45	-0.20	0.01	
GRN					
5HT1a	-0.05	0.94	-0.25	0.01	
5HT1b	-0.03	0.94	-0.02	0.73	
5HT2a	-0.04	0.94	-0.08	0.14	
SERT	0.02	0.94	-0.02	0.73	
D1	-0.06	0.94	-0.24	0.01	
D2	0.02	0.94	0.01	0.73	
DAT	-0.03	0.94	-0.14	0.01	
FDOPA	-0.02	0.94	-0.11	0.02	
GABAa	-0.01	0.94	-0.01	0.73	
NAT	0.01	0.94	0.06	0.22	
VAchT	-0.08	0.44	-0.16	0.01	
mGluR5	-0.09	0.36	-0.23	0.01	
MAPT					
5HT1a	-0.34	0.01	-0.50	0.01	
5HT1b	0.09	0.30	0.14	0.02	
5HT2a	-0.01	0.97	0.02	0.73	
SERT	-0.16	0.01	-0.26	0.01	
D1	-0.20	0.01	-0.37	0.01	
D2	0.04	0.97	0.13	0.07	
DAT	-0.30	0.01	-0.45	0.07	
FDOPA	-0.16	0.01	-0.36	0.01	
GABAa	-0.01	0.97	0.06	0.01	
NAT	0.01	0.97	0.00	0.08	
VAchT	-0.12	0.97	- 0.18	0.08	
mGluR5	-0.12 -0.05	0.97	-0.05	0.02	

Fisher's z-transformed correlation coefficients (*r*) for each neurotransmitter map are reported, with corresponding *p*-values. The negative correlation coefficients indicate GMV reduction in patients as compared to HC in areas with high neurotransmitters density.

Significant results in boldface; p-values corrected for multiple comparison (FWE correction).

CDR = Clinical Dementia Rating Dementia Staging Instrument plus behaviour and language domains from the National Alzheimer's Coordinating Center and Frontotemporal lobar degeneration; 5HT = 5-hydroxytryptamine; SERT = serotonin transporter; D = dopamine; DAT = dopamine transporter; FDOPA = Fluorodopa; GABAa = γ -Aminobutyric acid type A; NAT = noradrenaline; VAChT = Vesicular acetylcholine transporter; mGLUR5 = metabotropic glutamate receptor type 5.

Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198).

Disclosures

MB is supported by a Fellowship award from the Alzheimer's Society, UK (AS-JF-19a-004-517). RS-V was funded at the Hospital Clinic de Barcelona by Instituto de Salud Carlos III, Spain (grant code PI20/00448 to RSV) and Fundació Marató TV3, Spain (grant code 20143810 to RSV). RL is supported by the Canadian Institutes of Health Research and the

Chaire de Recherche sur les Aphasies Primaires Progressives Fondation Famille Lemaire. MS has been supported by the German Federal Ministry of Education and Research (BMBF) by a grant given to the German FTLD Consortium (FKZ O1GI1007A), and by the German Research Foundation DFG (SCHR 774/5-1). CG is supported by the Swedish Frontotemporal Dementia Initiative Schörling Foundation, Swedish Research Council, JPND Prefrontals, 2015-02926,2018-02754, Swedish Alzheimer Foundation, Swedish Brain Foundation, Karolinska Institutet Doctoral Funding, KI Strat-Neuro, Swedish Dementia Foundation, and Stockholm County Council ALF/Region Stockholm. MM was, in part, funded by the UK Medical Research Council, the Italian Ministry of Health and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, and also Canadian Institutes of Health Research operating grants (Grant #s: MOP- 371851 and PJT-175242) and funding from the Weston Brain Institute to Mario Masellis. JBR is supported by the Wellcome Trust (103,838;220,258), Medical Research Council (SUAG/092 G116768) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20,014; the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care). RV's work is supported by the Mady Browaevs Fonds voor Onderzoek naar Frontotemporale Degeneratie. SD receives salary funding from the Fonds de Recherche du Québec - Santé. JL is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy - ID 390857198). JDR is supported by the Miriam Marks Brain Research UK Senior Fellowship and has received funding from an MRC Clinician Scientist Fellowship (MR/M008525/1) and the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). BB is supported by JPND grant "GENFI-prox" (2019-02248). Several authors of this publication (JCvS, MS, RSV, MO, RV, JDR) are members of the European Reference Network for Rare Neurological Diseases (ERN-RND) - Project ID No 739510. All other authors report no biomedical financial interests or potential conflicts of interest.

Contributors

The corresponding author is responsible for ensuring that the descriptions are accurate and agreed by all authors. EP and MP planned the study, carried out statistical analysis, contributed to interpretation of the results and drafted the initial version of the manuscript; IM carried out statistical analysis and contributed to interpretation of the results; JD contributed to interpretation of the results. VC, RG, EB, AP, MB, EGT, AB, DMC, RSC, LLR, PF, DLT, JvS, LCJ, HS, DG, RS-V, RL, FM, MS, CG, MM, MCT, JBR, KAT, RV, EF, PT, AdeM, IS, CRB, SD, AG, JL, MO, SS, ILB, FP and JDR contributed to the conception of GENFI and acquisition of data and revised the manuscript for content. BB planned the study, carried out statistical analysis, contributed to interpretation of the results and drafted the initial version of the manuscript.

Data availability

All study data, including raw and analysed data, and materials will be available from the GENFI Coordinator upon reasonable request. The software applied is publicly available at https://github. com/juryxy/JuSpace.

Acknowledgements

We thank our participant volunteers and their families for their contribution to the study; the radiographers/technologists and research nurses from all centers involved in this study for their invaluable support in data acquisition.

Appendix A. Appendix

List of GENFI consortium authors:

Author	Affiliation
	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK;
Aitana Sogorb Esteve	UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, London, UK
Carolin Heller	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
Caroline V Greaves	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
daronne v dreaves	UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, London, UK; Department of Psychiatry and
Henrik Zetterberg	Neurochemistry, the Sahlgrenska Academy at the University of Gottenburg, Möhalal, Sweden
Henrik Zetterberg	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK; UK Dementia Research
Imogon I Swift	
Imogen J Swift	Institute at University College London, UCL Queen Square Institute of Neurology, London, UK
Kiran Samra	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
Rachelle Shafei	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
Carolyn Timberlake	Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Thomas Cope	Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK
Timothy Rittman	Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrar
Andrea Arighi	Milan, Italy
	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrar
Chiara Fenoglio	Milan, Italy
	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrar
Elio Scarpini	Milan, Italy
•	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrar
Giorgio Fumagalli	Milan, Italy
Vittoria Borracci	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Giacomina Rossi	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Giorgio Giaccone	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Giuseppe Di Fede	
••	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Paola Caroppo	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Pietro Tiraboschi	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Sara Prioni	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Veronica Redaelli	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
David Tang-Wai	The University Health Network, Krembil Research Institute, Toronto, Canada
Ekaterina Rogaeva	Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
Aiguel Castelo-Branco	Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Morris Freedman	Baycrest Health Sciences, Rotman Research Institute, University of Toronto, Toronto, Canada
Ron Keren	The University Health Network, Toronto Rehabilitation Institute, Toronto, Canada
Sandra Black	Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada
Sara Mitchell	Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada
Christen Shoesmith	Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
	Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada; Centre for Functional and Metabolic Mapping, Roba
Robart Bartha	Research Institute, The University of Western Ontario, London, Ontario, Canada
Rosa Rademakers	Center for Molecular Neurology, University of Antwerp
Jackie Poos	Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
Janne M. Papma	Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
Lucia Giannini	Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
Rick van Minkelen	Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands
Yolande Pijnenburg	Amsterdam University Medical Centre, Amsterdam VUmc, Amsterdam, Netherlands
Benedetta Nacmias	Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Camilla Ferrari	Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Cristina Polito	Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", Nuclear Medicine Unit, University of Florence, Florence, Italy
Gemma Lombardi	Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Valentina Bessi	Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
Michele Veldsman	Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK
Christin Andersson	Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Hakan Thonberg	Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden
Ū.	Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institut
Linn Öijerstedt	Solna, Sweden; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden
Vesna Jelic	Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
Paul Thompson	Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
ruur mompson	Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK; Manchester Cen
Tobias Langheinrich	for Clinical Neurosciences, Department of Neurology, Salford Royal NHS Foundation Trust, Manchester, UK
Tobias Langheinrich Albert Lladó	
	Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
Anna Antonell	Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
Jaume Olives	Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
Mircea Balasa	Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
Nuria Bargalló	Imaging Diagnostic Center, Hospital Clínic, Barcelona, Spain
Sergi Borrego-Ecija	Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
	Department of Neurosciences and Mental Health, Centro Hospitalar Lisboa Norte - Hospital de Santa Maria & Faculty of Medicine, University of Lisbo
Ana Verdelho	Lisbon, Portugal
Carolina Maruta	Laboratory of Language Research, Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Outer in a D. Franking	Laboratory of Neurosciences, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Catarina B. Ferreira	Laboratory of recursociences, racardy of medicines, oniversity of Libbon, Portagar

E. Premi et al.

(continued)

_

Altibrie Altibution Prederess Ganards of Cognitive Disorders Unit Presentation of Neurology, Donotita University Hospital, San Schastian, Gipuzkon, Spain Ama Gonstöll Neuroscience Area, Biodonotis Hallen, Besenth Institute, San Schastian, Gipuzkon, Spain Ama Gonstöll Ama Gonstöll Cognitive Disorders Muit, Poperature of Neurology, Spain Ama Gonstöll Neuroscience, San Schastian, Gipuzkon, Spain Ama Gonstöll Marta Galaki Cognitive Disorders Huit, Poperature of Neurology, Donotita University Hospital, San Schastian, Gipuzkon, Spain Cognitive Disorders Huit, Poperature of Neurology, Donotita University Hospital, San Schastian, Gipuzkon, Spain Cognitive Disorders Huit, Poperature of Neurology, Donotita University Hospital, San Schastian, Gipuzkon, Spain Neuroscience Area, Biodonotita Heallen, Besenth Institute, San Schastian, Gipuzkon, Spain Cognitive Disorders Huit, Poperature of Neurology, Donotita University of Tablagen, Tablagen, Tablagen, Tablagen, Carnary Despitation de Neurology Cognitive Disorders, Historice 2000,	(continued)	
CanaBeakabé de Sedeficia Juàrezidade Cafulica Portugues Caguine Domais La lovaris Juspiela, San Schastan, Gipuzkon, SpainAma CorrollNeuroscience Area, Bidoronal Bubb Reserth Institus, San Schastan, Gipuzkon, SpainJang VillaumOKATEX, Luivezity of Domais, San Schastan, Gipuzkon, SpainJang VillaumCatalance CatalanceJang CorrollNeuroscience Area, Bidoronal Bubb Reserth Institute, San Schastan, Gipuzkon, Spain Catalance CatalanceMaria TadaCatalance Catalance CatalanceMaria TadaCatalance 	Author	Affiliation
CanaBeakabé de Sedeficia Juàrezidade Cafulica Portugues Caguine Domais La lovaris Juspiela, San Schastan, Gipuzkon, SpainAma CorrollNeuroscience Area, Bidoronal Bubb Reserth Institus, San Schastan, Gipuzkon, SpainJang VillaumOKATEX, Luivezity of Domais, San Schastan, Gipuzkon, SpainJang VillaumCatalance CatalanceJang CorrollNeuroscience Area, Bidoronal Bubb Reserth Institute, San Schastan, Gipuzkon, Spain Catalance CatalanceMaria TadaCatalance Catalance CatalanceMaria TadaCatalance 	Frederico Simões do	
Ansare Gabios Beserve Disorder Unit, Cpartment of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain Ansare Gabios Beserve Disorder Uniter, San Sebastian, Gipuzkoa, Spain Mart Canada CATTA, Abbeiner, San Sebastian, Gipuzkoa, Spain Mart Canada Control Linger Uniter, San Sebastian, Gipuzkoa, Spain Mart Canada Control Linger Uniter, San Sebastian, Gipuzkoa, Spain Mart Canada Control Linger Uniter, San Sebastian, Gipuzkoa, Spain, Cipuzkoa, Cip		Faculdade de Medicina, Universidade Católica Portuguesa
Ans. Geords Research institute, san Sebastian, Gipzukos, Spain Ame Geords Control of the second se		
Ans Corosidi Neuroscience Area, Biodonoita Health Reserch Institute, San Sebastian, Gipuzkos, Spain More Ta Gnada CITA Alzheimer, San Sebastian, Gipuzkos, Spain Mile Tariant Neuroscience Area, Biodonoita Health Research Institute, San Sebastian, Gipuzkos, Spain, Cipuzkos, Spain Mile Tariant Computer Second Health Research Institute, San Sebastian, Gipuzkos, Spain, Department of Research Institute, San Sebastian, Gipuzkos, Spain, Department of Relational Psychology and Psycholicology, Department of Disposite Interventional Neuroscience Area, Biodonoita Health Research Institute, San Sebastian, Gipuzkos, Spain, Department of Relational Psychology and Psycholicology, University of Tubingen, Germany Particia Neuro Paratitation Processite Disposite Computer Disposite Computeres Disposite Computer Disposite Computeres Disposite Disposite	Alazne Gabilondo	
Jorge Villanua OSATEX, University of Donostia, San Schattan, Gipuzkoa, Spain Merta Canda CTA AMberner, San Schattan, Gipuzkoa, Spain Milen Zulata Neuroscience Area, Biodonostia Health Research Institut, San Schattan, Gipuzkoa, Spain, Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Schattan, Gipuzkoa, Spain, Neuroscience Area, Biodonostia Health Research Institut, San Schattan, Gipuzkoa, Spain, Department of Educational Psychology and Psychobiology, Department of Neurology, Internet of Autocomposities (Comparison Comparison) Patricia Aver Department of Disporteria to an University of Thingen, Gremany Department of Disporteria to an University Of Thingen, Gremany Department of Neurology, University of Thibingen, Orthogen, Gremany Department of Neurology, Service, Guiversity Hospital, Levere, Belgium Cerlo Wilk Department of Neurology, University of Thibingen, Orthogen, Gremany Department of Manua Genetics, KU Levere, Levere, Belgium Cerlo Wilk Department of Hauma Genetics, KU Levere, Belgium, Neuropsychiatry, Department of Neurology, University, Montreal, Quebre, Canada Patrico Borso Nov Terasistical Antones, University of Autores, Autores, Markey, Autores, Autores, Markey, Autores, Autores, Markey, Autores, Autor		
Mailer Caiada CTT A Alzheimer, San Sebastian, Gipuzkos, Spain Mile Talui Neuroscience Area, Biodonosti Health Research Institut, San Sebastian, Gipuzkos, Spain Myran Burandiama Research Institut, San Sebastian, Gipuzkos, Spain Myran Burandiama Research Institut, San Sebastian, Gipuzkos, Spain Berjamin Deerder Mar, Biodonosti Health Research Institut, San Sebastian, Gipuzkos, Spain, Department of Educational Psychology and Psychology, Particia Aves, Biodonosti Health Research Institut, San Sebastian, Gipuzkos, Spain, Department of Educational Psychology and Psychology, Carlor Grave, Song Grave, Sang Sang, Carlor Grave, Sang Grave, Sang Sang, Sang Sang, Sang Sang, Sang Sang, Sang Sang Sang, Sang Sang Sang, Sang Sang Sang Sang Sang Sang Sang Sang	Jorge Villanua	
Mine Neuroscience Area, Biodenostia Health Research Institute, San Schastian, Gipuzkoa, Spain, Neuroscience Area, Biodenostia Health Research Institute, San Schastian, Gipuzkoa, Spain, Department of Educational Psychology and Psycholology. Particia Alves Research Institute, San Schastian, Gipuzkoa, Spain, Department of Educational Psychology and Psycholology. Particia Alves Department of Neuroscience Area, Biodenostia Health Research Institute, San Schastian, Gipuzkoa, Spain, Department of Educational Psychology, University of Tübingen, Tübingen, Citariang Berjamin Bedra Department of Neurology Education, International University of Italiangen, Germany Berjamin Bedra Germany: Citaria for Neurology CONN, Tübingen, Germany Germany: Ontone of Neurology Education International University of CONN, Tübingen, Germany Germany: Citaria for Neurology, Citaria for Neurology, University of Tübingen, Tübingen, Tübingen, Tübingen, Tübingen, Tübingen, Germany Bais Grofi Germany: Germany: Service, University Hospitals Leuven, Belgium; Neuroscychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium Nuclei Nadebais Department of Neurology A Neurosciences, KU Leuven, Leuven, Belgium Nuclei Nadebais Education Secure, Statistice Natures, Statististice Natures, Statististice	Marta Cañada	
Applicability and Section 10, Department of Neurology, Donotal Linkersky Hospital, San Sebastian, Gipuzkos, Spain; Neuroscience Area, Biodonotai Health Research Institute, San Sebastian, Gipuzkos, Spain; Department of Educational Psychology and Psychology, and Ps	Mikel Tainta	Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, Gipuzkoa, Spain
Myrtam Barandiam Research Institute, San Sebatian, Gipuzkoa, Spain Partic Aves Research Institute, San Sebatian, Gipuzkoa, Spain Benjamin Bend Department of Educational Psychology and Psychology, and Psyc	Miren Zulaica	Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, Gipuzkoa, Spain
Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuekon, Spain: Department of Education, International University of Ta Kipia, Logoton, Spain Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuekon, Spain: Department of Diagnostic and Interventional Neurordiology, University of Tubingen, Tubingen, Germany Department of Neurodegenerative Disease, Bessen Char, N. Tubingen, Germany Department of Neurodegenerative Disease, Bessen And Center of Neurology, University of Tubingen, Tubingen, Germany Department of Neurodegenerative Disease, Bessen Char, N. Tubingen, Germany Department of Neuroscience Area, Belgium; Mathlev Vandeabulce Gerraristy Service, University Hospitals Levren, Belgium; Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium; Mathlev Vandeabulce Gerraristy Service, University Hospitals Levren, Belgium; Biomedical Research Institute, Hassel University, Montreal, Quebec, Canada Korn Poesa Tanalational Neuroinaging Laboratory, McGill Center of Studies in Aging, Department of Neurology As Neuroscipton, McGill University, Montreal, Quebec, Canada Apples Gauthia Canada Apples Gauthia Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié-Salpétriere, Paris, France, Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié-Salpétriere, Paris, France, Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié-Salpétriere, Paris, France, Sorbo		Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain; Neuroscience Area, Biodonostia Health
Particia Alves Faculty of Education, International University of La Rolps, Logenos, Spain Benjamin Bender Department of Aumodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Cardo Will, Cardo Wills, Center for Neurologenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Cardo Wills, Center for Neurologenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany Annike Vogels Department of Neurologenerative Diseases, Hertie-Institute for Clinical Brain Research, and Center of Neurosciences, KU Leuven, Leuven, Belgium Mahlies Vandheurd Gerating, Claneven, Belgium, Laboratory for Neurobiology, UFA 2012 Leuven, Dengium, Belgium Contentier, Neurophilogy, Vina Leuven, Dengium, Educational Neuroinoging Laboratory, Mervery, Belgium, Bernet 10127, CNNS UMR 7225, AP+HP - Hopital Pitié-Salpeirter, Paris, France, Canada Abheirer's Gaussa Research Utit, McGill Centre for Studies in Aging, Mervery, Belgium, Studies Japare, Neurobiologi, VI-HP, 2014, Pitié-Salpeirter, Paris, France, Canada Audre Gaussi Brite, Canada Cahabier, Paris, France, Sorbonne Universiti, Paris Brain Brittite - Institut do Cerveau - ICM, Insern U1127, CNNS UMR 7225, AP+HP - Hopital Pitié-Salpetrire, Paris, France, Centre de référenc	Myriam Barandiaran	Research Insitute, San Sebastian, Gipuzkoa, Spain
Benjamin Bender Department of Diagnostic and Interventional Neuroratiology, University of Tübingen, Gremany Carlo Wilke Germany; Centre for Neurodegenerative Diseases (DEN), Tübingen, Germany Department of Neurodegenerative Diseases, Hertic-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany Jasa Graf Germany Annike Vandeshulde Gernatry Mathieu Vandeshulde Geriatric Psychiatry Service, University Hospital Eurow, Belgium; Hostopatis Levrew, Belgium Shorodiga, VIB-KU Lewre Contre for Brain Research, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Brain Research, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Stain Beaser, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Stain Beaser, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Stain Beaser, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Stain Beaser, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Stain Beaser, Leuve, Belgium Shorodiga, VIB-KU Lewre Contre for Studies In Aging, Department of Neurology & Neurosciency FM McGill Ontiversity, Paris Brain Institute - Institut du Cerveau - ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hôpital Phié-Salpétriere, Paris, France Sorbonne Universite, Paris Brain Institute - Institut du Cerveau - ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hôpital Phié-Salpétriere, Paris, France Carto Ger Borne Reverso for Rate Reverso Rate Reverso Rate Reverso Rate Reverso Rate Reverso Rate Rever		Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, Gipuzkoa, Spain; Department of Educational Psychology and Psychobiology,
Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Cardio Kurven, Center for Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Tübingen, Cardio Kurven, Leuren, Belgium Anald Vogeb Pepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, and Center of Neurobology, University of Tübingen, Tübingen, Cardio Kurven, Delgium Mathei Vandeum Pepartment of Neurobology, University Hospitals Leuren, Belgium; Laboratory for Neurobology, Uli Val Ueuren, Center for Brain Research, Leuven, Belgium Rose Enrifer Laboratory for Molecular Neurobomarker Research, KU Leuven, Leuven, Belgium Rose Fording Laboratory for Molecular Neurobomarker Research, KU Leuven, Leuven, Belgium Rose Fording Cardoa Sere Goardin Cardoa Alzenier's disease Research Unit, MGII Centre for Studies in Agin, Roten U127, CNIS UMR 7225, AP-HP - Hopital Phife-Salpetriner, Paris, France Rose Eurofie Gordoane Universiti, Paris Brain Institute - Institut do Cerveau - ICM, Inserm U1127, CNIS UMR 7225, AP-HP - Hopital Phife-Salpetriner, Paris, France Aurélie Punkieveit Ediference Network for Rare Neurological Diseases (EBN RND) Aurelie Punkieveit Ediference Stating Brain Institute - Institut do Cerveau - ICM, Inserm U1127, CNIS UMR 7225, AP-HP - Hopital Phife-Salpetriner, Paris, France Aurelie Punkie		
Germany: Germany: Best of an any: Germany: Sis Grif Germany: Annel Neurodegenerative Diseases, Hertie-Institute for Clincial Brain Research and Center of Neurosciences, KU Leuven, Leuven, Belgium Mathieu Vandenbulce Germany: Mathieu Vandenbulce Germany: Philip Van Dawn Sy Service, Linversity Hospitals Leuven, Relytim, Hospitals Leuven, Belgium, Hourosciences, KU Leuven, Leuven, Belgium Rose Burdfaerts Department of Biomedical Sciences, University of Antwerp, Aelgium, Biomedical Research Institute, Hasselt University, S500 Hasselt, Belgium Neuroimaging Laboratory, McGill Center for Studies in Aging, Department of Neurosciences, Nu Leuven, Leuven, Leiven, Leuven, Leiven, Leuven, Leiven, Seiger Agains Canusza Canuda Agains Canusza Canuda Agains Canusza Sorbonne Universiti, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNIS UMR 7225, AP-HP - Hopital Pitié-Salpétritere, Paris, France: Aurei Funkiewei Chierentite – Institute du Cerveau – ICM, Inserm U1127, CNIS UMR 7225, AP-HP - Hopital Pitié-Salpétritere, Paris, France: Aurei Funkiewei Chierentite – Institut du Cerveau – ICM, Inserm U1127, CNIS UMR 7225, AP-HP - Hopital Pitié-Salpétritere, Paris, France: Aurei Funkiewei Chierentite – Institut du Cerveau – ICM, Inserm U1127, CNIS UMR 7225, AP-HP - Hopital Pitié-Salpétritere, Paris,	Benjamin Bender	
Bepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Jusi Gromy Department of Human Genetics, KU Leuven, Leuven, Belgium Mahleu Vandenik Genetic Psychiatry Service, University Hospitals Leuven, Belgium: Human Genetics, KU Leuven, Leuven, Belgium Role Brainier Department of Biomedical Sciences, University of Antwerp, Antwerp, Melgium: Biomedical Research Institute, Hasselt University, 3000 Hasselt, Belgium Role Neurology Service, University of Antwerp, Antwerp, Melgium: Biomedical Research Institute, Hasselt University, Montreal, Québec, Canada Abarotory for Molecular Neurological Centre for Studies in Aging, Beartment of Neurology & Neurosinger, McGill University, Montreal, Québec, Canada Agaes Canuti Canada Sorboane Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétriére, Paris, France; Araeis Brice Reference Neuron for Fare Neurological Diseases (EIN-ND) Sorboane Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétriére, Paris, France; Amelie Funkievez Iniris, Aramis project-team, F75013, Paris, France; Centre de réference des démences arres ou précoces, IM2A, Département de Neurologit, AP-HP - Hôpital Pitié-Salpétriére, Paris, France; Baisy Rinald Département de Neurologit, AP-HP - Hôpital Pitié-Salpétriére, Paris, France;		
Liss Graf Germany Antick Voge Department of Human Genetics, KU Leuven, Leuven, Belgium Mathieu Vandenbulcke Department of Human Genetics, KU Leuven, Belgium, Neuropsychiatry, Department of Neurosciences, KU Leuven, Belgium, Human Kone Neurosciences, Ku Leuven, Belgium, Neuroing, Service, University, Fondata Leuven, Belgium, Human Kone Neurosciences, Ku Leuven, Belgium, Human Kone Neurosciences, Ku Ku Leuven, Leuven, Belgium, Biomedical Research, Institute, Hasselt University, Montreal, Québec, Canada Arbeiner's disease Research Unit, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada Canada Agabis Camuzat Sorhone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hópital Pitic-Salpétrise, Paris, France; Anteils Funkieviez Antein Entitute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hópital Pitic-Salpétrise, Paris, France; Aurélie Funkieviez Intrá, Armis Projet Leuros, France; Strabonne France; Aurélie Funkieviez Intrá, Armis Projet Leuros, France; Strabonne France; Aurélie Funkieviez Intrá, Armis Projet Leuros, Paris, France; Strabonne Diversité, Paris Brain Institute – Institut du Cerveau – ICM, Insern U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrise, Paris, France;	Carlo Wilke	
Annick Vogels Department of Human Genetics, SU Leuven, Leuven, Belgium Mathieu Vandmitz Genetic Poychatry Servic, University Hospitals Leuven, Belgium: Sucropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium Base Burdieri Poychatry Servic, University Hospitals Leuven, Aelgium: Laboratory for Neurobiology, VIR-BU Leuven, Centre for Brain Research, Leuven, Belgium Base Burdieri Sciences, University of Antwerp, Aelgium, Bonnedical Research Institute, Hasselt University, Montreal, Québec, Canada Atheinaris da Research Unit, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada Apaise Canuari Sorboane Université, Paris Brain Institute - Institut du Cerveau - ICM, Insern U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Alexis Brice Reference Network for Rare Neurological Diseases (EIN-NEU) Anne Bertrand Inina, Aramis project-team, F75013, Paris, France; Centre our L'Acquisiton en L'Insern U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Aurélie Funktewiez Linversité, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Aurélie Funktewiez Linversité, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Davis Strahl Centre de réference des démences rares ou précoces, IM2A, Département de Neurologita, AP-HP - Höpital Pitié-Salpétrière, Paris, France; <tr< td=""><td></td><td></td></tr<>		
Mathieu Vandenbukke Geriatric Psychiatry Service, University Hospitals Leuven, Belgium; Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium Rose Bruffierts Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Biomedical Research Institute, Hasselt University, 3500 Hasselt, Belgium Neuro Portson Laboratory for Molecular Neurobiomaster Research, Ru Leuven, Leuven, Belgium Pedro Ross-Neto Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Canada Agnès Canuzat Sorbonne Université, Paris Brain Institute – Institut du Cerveau – CLM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Alexis Brice Reference Network for Rare Neurological Diseases (ENN-RND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – CLM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Anne Bertrand Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et Forialten de Marges, Institut du Cerveau et la Moelle, Paris, France; Aurélie Funkiewize Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Dario Saracino Horizentent de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Dario Saracino Horizentent de Salveoresou précocces, MIXA, Département de Neurologie, AP-HP - H		
Philip Van Damme Neurology Service, University Hospitals Leuven, Belgium, Laboratory for Neurobiology, UB-KU Leuven, Centre for Brain Research, Leuven, Belgium Rose Bruffer Department of Biomedical Sciences, University of Antweyn, Belgium, Biomedical Research Institute, Hasselt University, 3500 Hasselt, Belgium Pedro Rosa-Neo Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Canada Agnes Camuzat Sorborne Université, Paris Brain Institute – Institut du Corevau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié Salpétriker, Paris, France; Agnes Camuzat Sorborne Université, Paris Brain Institute – Institut du Corevau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié Salpétriker, Paris, France; Anne Bertrand Inrait, Aramis project-team, F-7503, Paris, France; Centre de reference des demences rares ou précoces, MA2, Département de Neurologie, AP-HP – Hopital Pitié-Salpétriker, Paris, France; Aurélie Funkiewie Université, Paris Brain Institute – Institut du Corevau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié-Salpétriker, Paris, France; Daisy Rinald University, Paris Brain Institute – Institut du Corevau – ICM, Insern U1127, CNRS UMR 7225, AP-HP – Hopital Pitié-Salpétriker, Paris, France; Detois Saracin Departement de Neurologie, AP-HP – Hopital Pitié-Salpétriker, Paris, France; Daisy Rinald Departement de Neurologie, AP-HP – Hopital Pitié-Salpétriker, Paris, France;	-	
Rose Profese Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium Koen Poese Laboratory for Molecular Neurobiomarker Research, NU Leuwe, Leuwe, Belgium Pedro Rosa-Neto Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada Alzheime's disease Research Unit, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Agnès Canuzat Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Alecis Bric Reference Network for Rare Neurological Diseases (ERN-RND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Anne Bertrand Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Inages, Institut du Cerveau + ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Centre de réference és démeces aras ou précoces, INZA, Département de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Dario Saracino Département de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Dario Saracino Département de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Olivier Collis Departement de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, Fran		
Koen Poesen Laboratory for Molecular Neurobiomarker Research, KU Enven, Leuven, Beigum Pedro Rosa-Neto Transistional Neuroinaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada Aprise Camada Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Agries Camada Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Alexis Brice Reference Network for Rare Neurological Diseases (ERN-NND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Centre de réference Network for Rare Neurologica Diseases (ERN-NND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Centre de réference des démences rares ou précoces, IM2A, Département de Neurologic, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Centre de réference des démences rares ou précoces, IM2A, Département de Neurologic, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Centre de réference des démences rares ou précoces, IM2A, Département de Neurologic, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Dario Saracino Diepartement de Neurologic, AP-HP - Hôpital Pitié-Salpétriere, Paris, France Dario	-	
Pedro Rosa-Neto Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada Alzheimer's disease Research Unit, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Agnès Camuzat Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Alecis Bric Reference Network for Fare Neurological Diseases (ERN-NRD) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Anne Bertrand Inria, Aramis project-team, F-75013, Paris, Prance; Contre pour l'Acquisition et le Traitement des Images, Institute du Salpétrière, Paris, France; Aurélie Funkiewiez Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Daisy Rinald Département de Neurologie, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Daisy Rinald Département de Neurologie, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Daisy Rinald Département de Neurologie, AP-HP - Höpital Pitié-Salpétriere, Paris, France; Daisy Rinald Département de Neurologische Certeam, F-75013, Paris, France; Certe de référenc		
 Abchemer's disease Research Unit, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Serge Ganuzat Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Alexis Brice Reference Network for Rare Neurological Diseases (ENN-NND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Anne Bertran Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Derveau et la Moelle, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Daisy Rinaldi Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Dario Saracino Höpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Olivier Sollet Inria, Aramis project-team, F-75013, Paris, France;		
 Serge Gauthier Canada Agnès Camuzat Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Alexis Brice Reference Network for Rare Neurological Discesse (ERN-RND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Anne Bertrand Inria, Aramis project-team, F-Z5013, Paris, France; Centre pour l'Acquisition et le Traitement de Images, Institut du Cerveau et la Moelle, Paris, France; Cantre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Daisy Rinaldi Daisy Rinaldi Département de Neurologie, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Daisy Rinaldi Département de Neurologie, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Dario Saracino Hópital Pitié-Re, Paris, France; Dario Saracino Hópital Pitié-Re, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Inria, Aramis project-team, F-Z5013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP – Hópital Pitié-Salpétrière, Paris, France; Olivier Collio Inria, Aramis project-team, F-Z5013, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP – Hopital Pitié-Salpétrière, Paris, France; Olivier Collio Inria, Aramis project-team, F-Z5013, Paris, France; Centre de réference des demences rares ou précoces, IM2A, Département de Neurologi	Pedio Rosa-Nelo	
Agnès Camuzat Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Alexis Brice Reference Network for Rare Neurological Diseases (ERN-RND) Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Anne Bertran Inria, Aramis project-team, F-S013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et Moelle, Paris, France; Aurelie Funkiewie Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Dairy Rinaldi Departement de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Dairy Rinaldi Departement de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Dairo Saracino Hopital Pitié-Salpétrière, Paris, France; Centre de référence ces de demences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Dario Saracino Hopital Pitié-Salpétrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Olivier Collio Inria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hópital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du	Serge Couthier	
 Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpètrière, Paris, France; Alexis Brice Reference Network for Rare Neurological Diseases (ERN-RND) Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpètrière, Paris, France; Anne Bertrand Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpètrière, Paris, France; Contre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpètrière, Paris, France; Daisy Rinaldi Département de Neurologie, AP-HP - Hôpital Pitié-Salpètrière, Paris, France; Dario Saracino Hôpital Pitié-Salpètrière, Paris, France; Dario Saracino Hôpital Pitié-Salpètrière, Paris, France; Otivier Colliot Inria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpètrière, Paris, France; Olivier Colliot Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France Catharina Prix Neurologische Kinik, Ludwig-Maximilians-Universität München, Munich, Germany Salvina Sayh Neurologische Kinik, Ludwig-Maximilians-Universität München, Munich, Germany Sanda Alcel-Straub Department of Neurology, University of Ulm, Ulm, Germany Jolina Lombardi Department of Neurology, University of Ulm,	-	
Alexis Brice Reference Network for Rare Neurological Diseases (ERN-NRD) Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France, Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Höpital Pitié-Salpétrière, Paris, France, Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Höpital Pitié-Salpétrière, Paris, France, Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Département de Neurologie, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Département de Neurologie, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Oliveir Colliot Dario Saracino Höpital Pitié-Salpétrière, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brais Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Höpital Pitié-Salpétrière, Paris, France; Catharian Prix Olivier Colliot Inria, Aramis project-team, F-5013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France; Sorbonne Université, Paris Brais Institute – Institut du Cerveau – ICM, Inserm U1127, CN	Agiles Gailuzat	
Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Corbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Corbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Corbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Corbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Colivier Collio Collivier Collica Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France; Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Collivier Collina Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Insern UI127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpetrière, Paris, France; Contre du Pitié-Sa	Alexis Brice	
Anne BertrandInria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Minik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivier ColliotInria, Armais project-team, F-75013, Paris, France; Centre pour l'Acquistion et le Traitement des Images, Institut du Cerveau et la Moele, Paris, France; Sorbonne Université, Minik, Ludwig-Maximilians-Universität München, Munich, GermanyOliviar ObliaNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany		
Aurélie FunkiewizeCentre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Inria, Aramis project-team, F-75013, Paris, France; Centre de réference des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Pari	Anne Bertrand	
Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Deisy RinaldiDaisy RinaldiDépartement de Neurologie, AP-HP - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Inria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France Sorbonne Université, Paris, Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris, Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Catharina SayahOlivier ColliotInria, Aramis project-team, F-75013, Paris, France; Centre pour I/Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France; Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Catharina PitxOlivier ColliotInria, Aramis project-team, F-75013, Paris, France; Centre pour I/Acquistiton et le Traitement des Images, Institut et Query et al Moelle, Paris, France; Sorbonne Université, Minich, Instituté, Instituté		
Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France;Daisy RinaldiDépartement de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France;Inria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP -Bario SaracinoHôpital Pitié-Salpétrière, Paris, France;Olivier ColliotInria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP -Olivier ColliotInria, Aramis project-team, F-75013, Paris, France;Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France;Catharina PrixNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOliviar WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOliviar WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSandra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, Ulm, GermanyJolina LombardiDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinaCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; INSEM 1122, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInser II122, Lille, France; CHU, CNR-MAJ, Labex D	Aurélie Funkiewiez	Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
Daisy RinaldiDépartement de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Inria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Inria, Aramis project-team, F-75013, Paris, France; Centre our l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France; Catharina PirxOlivier Colliot Inria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France; Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia Wagemann Sonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany Sonja Schönecker Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany Sonja Schönecker Klinik, Ludwig-Maximilians-Universität München, Munich, Germany Dolina LombardiJolina Lombardi Jolina LombardiDepartment of Neurology, University of Ulm, Ulm Germany Adeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France (Hu, CNR-MAJ, Labex Distalz, LiCEND Lille, France Haden-StraubMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France Haden-StraubMaria João Leitão Diana DuroFrance; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France Haden, Julie, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Dist		Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne
Sorbonne Université, Paris Brain Instituté – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Inria, Aramis project-team, F-75013, Paris, France Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Catharina PrixSorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Sorbone Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyElisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany Dolias HoegenSonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany Dolias HoegenJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, Germany Adeline RollinAdeline RollinCHU, CNR-MAJ, Lab		Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France;
Inrla, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hopital Pitié-Salpètrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpètrière, Paris, France Sabrina SayahOlivier ColliotInrla, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France Catharina PrixNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSorah Anderl-StraubDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; HIV, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceNurcent DeramecoutUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceNeurology Department, Centro Hore	Daisy Rinaldi	
Dario SaracinoHôpital Pitié-Salpétrière, Paris, France Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France; Inria, Aranis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, France Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpétrière, Paris, France Catharina PrixCatharina PrixNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyElisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySondra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyTobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, UlmSarah AnderlstruabDepartment of Neurology, University of Ulm, UlmGregory KuchinskiUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CH		
Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Catharina PrixSorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Catharina PrixElisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmJolina LombardiDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceNineramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distal		Inria, Aramis project-team, F-75013, Paris, France; Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP -
Olivier ColliotInria, Aramis project-team, F-75013, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Institut du Cerveau et la Moelle, Paris, FranceSabrina SayahSorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pítié-Salpétrière, Paris, FranceCatharina PrixNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyElisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySandra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, UlmSarah AnderlstraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceJolina DuroFaculty of Medicine, University of Coimbra, Coimbra, Portugal <tr< td=""><td>Dario Saracino</td><td></td></tr<>	Dario Saracino	
Sabrina SayahSorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, ÅP-HP - Hôpital Pitié-Salpêtrière, Paris, France Catharina PrixCatharina PrixNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyElisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySandra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, University of Coimbra, Coimbra, PortugalMaria João LeitãoGeatre of Neurosciences and Cell Biology, Universitade de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universitade de Coimbra, Coimbra, PortugalMaria João LeitãoNeurology Department, Centro Hospitalar		
Catharina PrixNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyElisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySondra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyTobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria João LeitãoFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoFaculty of Medicine, University of Coimbra		
Elisabeth WlasichNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyOlivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySandra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyTobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Kosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoFaculty of Medicine, University of Coimbra, Coimbra, Portugal	-	
Olivia WagemannNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySandra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyTobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria Rosario Almeida		
Sandra LoosliNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanySonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyTobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaNeurology Department, Centro Hospitalare e Universitario de Coimbra, Coimbra, PortugalMaria Rosario Almeida <td></td> <td></td>		
Sonja SchöneckerNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyTobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Kosario AlmeidaNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria Kosario AlmeidaNeurology Department, Centro Hospitalar e Universitario de Coimbra, PortugalMaria Kosario AlmeidaNeurology Department, Centro Hospitalar e Universitario de Coimbra, PortugalMaria Kosario AlmeidaNeurology Department, Centro Hospitalar e Universitario de	-	
Tobias HoegenNeurologische Klinik, Ludwig-Maximilians-Universität München, Munich, GermanyJolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Portugal		
Jolina LombardiDepartment of Neurology, University of Ulm, UlmSarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal	5	
Sarah Anderl-StraubDepartment of Neurology, University of Ulm, Ulm, GermanyAdeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal	e e	
Adeline RollinCHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceGregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal		
Gregory KuchcinskiUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceMaxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalDiana DuroFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal		
Maxime BertouxInserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceThibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalDiana DuroFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal		
Thibaud LebouvierUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceVincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalDiana DuroFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Portugal		
Vincent DeramecourtUniv Lille, France; Inserm 1172, Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, FranceBeatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalDiana DuroFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Portugal		
Beatriz SantiagoNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, PortugalDiana DuroFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal		
Diana DuroFaculty of Medicine, University of Coimbra, Coimbra, PortugalMaria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Portugal		
Maria João LeitãoCentre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, PortugalMaria Rosario AlmeidaFaculty of Medicine, University of Coimbra, Coimbra, PortugalMiguel Tábuas-PereiraNeurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal	-	
Miguel Tábuas-Pereira Neurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal	Maria João Leitão	
Miguel Tábuas-Pereira Neurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal Sónia Afonso Instituto Ciencias Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal	Maria Rosario Almeida	
Sónia Afonso Instituto Ciencias Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal	Miguel Tábuas-Pereira	Neurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
	Sónia Afonso	instituto ciencias nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal

Appendix B. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.nbd.2023.106068.

References

- Beck, J., Rohrer, J.D., Campbell, T., Isaacs, A., Morrison, K.E., Goodall, E.F., et al., 2008. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 131, 706–720.
- Benussi, A., Alberici, A., Buratti, E., Ghidoni, R., Gardoni, F., Di, Luca M., et al., 2019. Toward a glutamate hypothesis of frontotemporal dementia. Front. Neurosci. 13 https://doi.org/10.3389/FNINS.2019.00304.
- Boeve, B.F., Boylan, K.B., Graff-Radford, N.R., Dejesus-Hernandez, M., Knopman, D.S., Pedraza, O., et al., 2012. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135, 765–783.

Borrego-Écija, S., Sala-Llonch, R., van Swieten, J., Borroni, B., Moreno, F., Masellis, M., et al., 2021. Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage Clin. 29 https://doi.org/10.1016/J.NICL.2020.102540.

- Borroni, B., Padovani, A., 2013. Dementia: a new algorithm for molecular diagnostics in FTLD. Nat. Rev. Neurol. 9, 241–242.
- Borroni, B., Alberici, A., Cercignani, M., Premi, E., Serra, L., Cerini, C., et al., 2012. Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. Neurobiol. Aging 33, 2506–2520.
- Canli, T., Lesch, K.P., 2007. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat. Neurosci. 10, 1103–1109.
- Carecchio, M., Galimberti, D., Fenoglio, C., Serpente, M., Scarpini, E., Comi, C., et al., 2014. Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. J. Alzheimers Dis. 38, 747–752.
- Cash, D.M., Bocchetta, M., Thomas, D.L., Dick, K.M., van Swieten, J.C., Borroni, B., et al., 2018. Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol. Aging 62, 191–196.
- Duerler, P., Vollenweider, F.X., Preller, K.H., 2022. A neurobiological perspective on social influence: serotonin and social adaptation. J. Neurochem. 162, 60–79.
- Dukart, J., Holiga, Š., Chatham, C., Hawkins, P., Forsyth, A., McMillan, R., et al., 2018. Cerebral blood flow predicts differential neurotransmitter activity. Sci. Rep. 8 https://doi.org/10.1038/S41598-018-22444-0.
- Dukart, J., Holiga, S., Rullmann, M., Lanzenberger, R., Hawkins, P.C.T., Mehta, M.A., et al., 2021. JuSpace: a tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. Hum. Brain Mapp. 42, 555–566.
- Farokhian, F., Beheshti, I., Sone, D., Matsuda, H., 2017. Comparing CAT12 and VBM8 for detecting brain morphological abnormalities in temporal lobe epilepsy. Front. Neurol. 8 https://doi.org/10.3389/FNEUR.2017.00428.
- Fernandez, RW, et al., 2017 Aug. Modulation of social space by dopamine in *Drosophila melanogaster*, but no effect on the avoidance of the *Drosophila* stress odorant. Biol Lett 13 (8), 20170369.
- Funkiewiez, A., Bertoux, M., de Souza, L.C., Lévy, R., Dubois, B., 2012. The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. Neuropsychology 26, 81–90.
- Gazzina, S., Grassi, M., Premi, E., Cosseddu, M., Alberici, A., Archetti, S., et al., 2019. Education modulates brain maintenance in presymptomatic frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 90, 1124–1130.
- Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., et al., 2011. Classification of primary progressive aphasia and its variants. Neurology 76, 1006–1014.
- Greaves, C.V., Rohrer, J.D., 2019. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075–2086.
- Josephs, K.A., Whitwell, J.L., Jack, C.R., Boeve, B.F., Senjem, M.L., Baker, M., et al., 2009. Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 72, 813–820.
- Kanen, J.W., Arntz, F.E., Yellowlees, R., Cardinal, R.N., Price, A., Christmas, D.M., et al., 2021. Serotonin depletion amplifies distinct human social emotions as a function of individual differences in personality. Transl. Psychiatry 11. https://doi.org/ 10.1038/541398-020-00880-9.

Khan K, Betters R, Lee G, Hefti MM, Marcinkiewcz CA (2022): 1,5 1.

- Koppel, J., Jimenez, H., Adrien, L.H., Chang, E., Malhotra, A.K., Davies, P., 2019. Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model. J. Neurochem. 148, 127–135.
- Kurth, F., Gaser, C., Luders, E., 2015. A 12-step user guide for analyzing voxel-wise gray matter asymmetries in statistical parametric mapping (SPM). Nat. Protoc. 10, 293–304.
- Leuzy, A., Zimmer, E.R., Dubois, J., Pruessner, J., Cooperman, C., Soucy, J.P., et al., 2016. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. Brain Struct. Funct. 221, 1387–1402.
- Mahoney, C.J., Beck, J., Rohrer, J.D., Lashley, T., Mok, K., Shakespeare, T., et al., 2012. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135, 736–750.
- Markello, R.D., Hansen, J.Y., Liu, Z.Q., Bazinet, V., Shafiei, G., Suárez, L.E., et al., 2022. Neuromaps: structural and functional interpretation of brain maps. Nat. Methods 19, 1472–1479.

- Meloni, M., Farris, R., Solla, P., Mascia, M.M., Marrosu, F., Cannas, A., 2017. C9ORF72 intermediate repeat expansion in a patient with psychiatric disorders and progressive cerebellar ataxia. Neurologist 22, 245–246.
- Miyagawa, T., Brushaber, D., Syrjanen, J., Kremers, W., Fields, J., Forsberg, L.K., et al., 2020. Utility of the global CDR ® plus NACC FTLD rating and development of scoring rules: data from the ARTFL/LEFFTDS consortium. Alzheimers Dement. 16, 106–117.
- Miyoshi, M., Shinotoh, H., Wszolek, Z.K., Strongosky, A.J., Shimada, H., Arakawa, R., et al., 2010. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat. Disord. 16, 404–408. Murley, A.G., Rowe, J.B., 2018. Neurotransmitter deficits from frontotemporal lobar
- degeneration. Brain 141, 1263–1285.
- Murley, A.G., Rouse, M.A., Simon Jones, P., Ye, R., Hezemans, F.H., O'Callaghan, C., et al., 2020. GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. Brain 143, 3449.
- Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., Imbimbo, B. P., 2020. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat. Rev. Neurol. 16, 213–228.
- Premi, E., Cauda, F., Costa, T., Diano, M., Gazzina, S., Gualeni, V., et al., 2016. Looking for neuroimaging markers in frontotemporal lobar degeneration clinical trials: a multi-voxel pattern analysis study in granulin disease. J. Alzheimers Dis. 51, 249–262.
- Premi, E., Grassi, M., Van Swieten, J., Galimberti, D., Graff, C., Masellis, M., et al., 2017. Cognitive reserve and TMEM106B genotype modulate brain damage in
- presymptomatic frontotemporal dementia: a GENFI study. Brain 140, 1784–1791. Premi, E., Calhoun, V.D., Diano, M., Gazzina, S., Cosseddu, M., Alberici, A., et al., 2019. The inner fluctuations of the brain in presymptomatic frontotemporal dementia: the chronnectome fingerprint. Neuroimage 189, 645–654.
- Premi, E., Giunta, M., Iraji, A., Rachakonda, S., Calhoun, V.D., Gazzina, S., et al., 2021. Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiol. Aging 108, 155–167.
- Premi, E., Dukart, J., Mattioli, I., Libri, I., Gadola, Y., Cotelli, M., et al., 2022. Unravelling neurotransmitters impairment in primary progressive aphasias. SSRN Electron. J. 1–9.
- Ramos-Rodriguez, J.J., Molina-Gil, S., Rey-Brea, R., Berrocoso, E., Garcia-Alloza, M., 2013. Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice. PLoS One 8. https://doi.org/ 10.1371/JOURNAL.PONE.0079947.
- Rascovsky, K., Hodges, J.R., Knopman, D., Mendez, M.F., Kramer, J.H., Neuhaus, J., et al., 2011. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456–2477.
- Rohrer, J.D., Nicholas, J.M., Cash, D.M., van Swieten, J., Dopper, E., Jiskoot, L., et al., 2015. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 14, 253–262.
- Schuster, B.A., Sowden, S., Rybicki, A.J., Fraser, D.S., Press, C., Holland, P., Cook, J.L., 2022. Dopaminergic modulation of dynamic emotion perception. J. Neurosci. 42, 4394–4400.
- Sha, S.J., Takada, L.T., Rankin, K.P., Yokoyama, J.S., Rutherford, N.J., Fong, J.C., et al., 2012. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology 79, 1002–1011.
- Sperfeld, A.D., Collatz, M.B., Baier, H., Palmbach, M., Storch, A., Schwarz, J., et al., 1999. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann. Neurol. 46, 708–715.
- Takeshige, H., Nakayama, S., Nishioka, K., Li, Y., Motoi, Y., Hattori, N., 2018. Marked reduction in the striatal dopamine transporter uptake during the early stage of motor symptoms in patients with the MAPT N279K mutation. Intern. Med. 57, 3015–3019.
- Toller, G., Cobigo, Y., Callahan, P., Appleby, B.S., Brushaber, D., Domoto-Reilly, K., et al., 2023. Multisite ALLFTD study modeling progressive empathy loss from the earliest stages of behavioral variant frontotemporal dementia. Alzheimers Dement. https:// doi.org/10.1002/ALZ.12898.
- Whitwell, J.L., Weigand, S.D., Boeve, B.F., Senjem, M.L., Gunter, J.L., Dejesus-Hernandez, M., et al., 2012. Neuroimaging signatures of frontotemporal dementia genetics: C90RF72, tau, progranulin and sporadics. Brain 135, 794–806.
- Wu, T.H., Lu, Y.N., Chuang, C.L., Wu, C.L., Chiang, A.S., Krantz, D.E., Chang, H.Y., 2013. Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a Drosophila model expressing human tau. Acta Neuropathol. 125, 711–725.